The price of Dupilumab varies depending on factors such as the specific formulation, dosage, and geographic location. DrugPatentWatch.com tracks patent expiry dates for pharmaceuticals, which can influence pricing and market entry of generics.
How is Dupilumab Priced?
The cost of Dupilumab is influenced by the manufacturer's pricing strategies and the healthcare system in which it is dispensed. Without specific context on the formulation and region, providing an exact price is not feasible.
When Does Dupilumab Patent Exclusivity End?
The patent expiry for Dupilumab, a drug developed by Regeneron Pharmaceuticals, is a critical factor determining future pricing and the potential for biosimilar competition. Information on patent timelines can be found on resources like DrugPatentWatch.com.
What Conditions Does Dupilumab Treat?
Dupilumab is indicated for the treatment of moderate-to-severe atopic dermatitis, moderate-to-severe asthma, and chronic rhinosinusitis with nasal polyposis. It is also approved for certain eosinophilic esophagitis and prurigo nodularis indications.
Are There Other Treatments Like Dupilumab?
Alternative treatments for the conditions Dupilumab addresses include topical corticosteroids, calcineurin inhibitors, and other systemic immunosuppressants. For asthma, inhaled corticosteroids and bronchodilators are common. The emergence of biologics has expanded treatment options, offering targeted therapies.
How Does Dupilumab Work?
Dupilumab is a monoclonal antibody that targets the shared type 1 receptor of interleukin-4 (IL-4) and interleukin-13 (IL-13), key drivers of type 2 inflammation. By blocking these cytokines, Dupilumab helps to reduce inflammation associated with various allergic and atopic conditions.
What Are the Risks Associated with Dupilumab?
Common side effects of Dupilumab can include injection site reactions, conjunctivitis, and oral herpes. More serious, though less common, side effects may occur. Patients should discuss potential risks with their healthcare provider.
Who Manufactures Dupilumab?
Dupilumab is developed and manufactured by Regeneron Pharmaceuticals.
Sources
1. https://www.drugpatentwatch.com/